Prognostic Value of Ezrin in Solid Tumors: a Meta-analysis of the Literature

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jul 30

PMID 23894313

Citations 7

Authors

Kun Han

Weixiang Qi

Zhihua Gan

Zan Shen

Yang Yao

Daliu Min

Affiliations

Soon will be listed here.

Abstract

Purpose: Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial.

Methods: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

Results: Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60-2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0-3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year.

Conclusions: Our findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

Citing Articles

Ezrin Immunoexpression in Prostate Adenocarcinomas.

Popescu T, Stepan A, Florescu M, Simionescu C Curr Health Sci J. 2023; 48(4):413-417.

PMID: 37304805 PMC: 10248486. DOI: 10.12865/CHSJ.48.04.08.

The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta-analysis.

Wang F, Yu T, Ma C, Zhang H, Zhang Z FEBS Open Bio. 2019; 9(10):1744-1755.

PMID: 31376222 PMC: 6768105. DOI: 10.1002/2211-5463.12713.

The Prognostic Value of Nanog Overexpression in Lung Cancer: A Meta-Analysis.

Cheng W, Wang H, Yuan J, Cheng Z, Xing D, Zhang M Biomed Res Int. 2019; 2018:3429261.

PMID: 30627549 PMC: 6304555. DOI: 10.1155/2018/3429261.

Immunohistochemical Expression Of Ezrin In Oral Potentially Malignant Disorders-A Descriptive Study.

Mohanraj R, Ramani P, Premkumar P, Natesan A, Sherlin H, Sukumaran G J Pharm Bioallied Sci. 2017; 9(Suppl 1):S205-S210.

PMID: 29284965 PMC: 5731014. DOI: 10.4103/jpbs.JPBS_139_17.

The Prognostic Value of Decreased LKB1 in Solid Tumors: A Meta-Analysis.

Xiao J, Zou Y, Chen X, Gao Y, Xie M, Lu X PLoS One. 2016; 11(4):e0152674.

PMID: 27035914 PMC: 4818087. DOI: 10.1371/journal.pone.0152674.

References

Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkila S, Vaheri A . Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol. 2008; 39(12):1737-43. DOI: 10.1016/j.humpath.2008.04.020. View

Kobel M, Langhammer T, Huttelmaier S, Schmitt W, Kriese K, Dittmer J . Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol. 2006; 19(4):581-7. DOI: 10.1038/modpathol.3800567. View

Huang H, Li C, Fang F, Tsai J, Li S, Lee Y . Prognostic implication of ezrin overexpression in myxofibrosarcomas. Ann Surg Oncol. 2010; 17(12):3212-9. DOI: 10.1245/s10434-010-1185-y. View

Korkeila E, Syrjanen K, Bendardaf R, Laulajainen M, Carpen O, Pyrhonen S . Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer. Hum Pathol. 2010; 42(3):384-92. DOI: 10.1016/j.humpath.2010.08.004. View

Carneiro A, Bendahl P, Akerman M, Domanski H, Rydholm A, Engellau J . Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. J Clin Pathol. 2011; 64(8):689-94. DOI: 10.1136/jcp.2011.089805. View

Yu Y, Khan J, Khanna C, Helman L, Meltzer P, Merlino G . Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004; 10(2):175-81. DOI: 10.1038/nm966. View

Yeh T, Tseng J, Liu N, Chen T, Jan Y, Chen M . Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg. 2005; 140(12):1184-90. DOI: 10.1001/archsurg.140.12.1184. View

Mhawech-Fauceglia P, Dulguerov P, Beck A, Bonet M, Allal A . Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy. J Clin Pathol. 2006; 60(2):185-9. PMC: 1860631. DOI: 10.1136/jcp.2006.036624. View

Kang Y, Hong S, Lee H, Kim W . Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog. 2010; 49(9):798-804. DOI: 10.1002/mc.20653. View

10.

Weng W, Ahlen J, Astrom K, Lui W, Larsson C . Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005; 11(17):6198-204. DOI: 10.1158/1078-0432.CCR-05-0548. View

11.

Moilanen J, Lassus H, Leminen A, Vaheri A, Butzow R, Carpen O . Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol. 2003; 90(2):273-81. DOI: 10.1016/s0090-8258(03)00262-2. View

12.

Xie J, Xu L, Wu Z, Zhao Q, Xu X, Wu J . Prognostic implication of ezrin expression in esophageal squamous cell carcinoma. J Surg Oncol. 2011; 104(5):538-43. DOI: 10.1002/jso.21909. View

13.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

14.

Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A . The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10(2):182-6. DOI: 10.1038/nm982. View

15.

Kobel M, Gradhand E, Zeng K, Schmitt W, Kriese K, Lantzsch T . Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol. 2006; 25(2):121-30. DOI: 10.1097/01.pgp.0000185410.39050.ac. View

16.

Bretscher A, Edwards K, Fehon R . ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002; 3(8):586-99. DOI: 10.1038/nrm882. View

17.

Wang L, Lin G, Jiang X, Lu Y . Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma. Tumour Biol. 2011; 32(4):707-12. DOI: 10.1007/s13277-011-0171-8. View

18.

Jorgren F, Nilbert M, Rambech E, Bendahl P, Lindmark G . Ezrin expression in rectal cancer predicts time to development of local recurrence. Int J Colorectal Dis. 2012; 27(7):893-9. DOI: 10.1007/s00384-011-1397-z. View

19.

Lee H, Kim E, Oh M . Clinicopathologic implication of ezrin expression in non-small cell lung cancer. Korean J Pathol. 2012; 46(5):470-7. PMC: 3490123. DOI: 10.4132/KoreanJPathol.2012.46.5.470. View

20.

Curto M, McClatchey A . Ezrin...a metastatic detERMinant?. Cancer Cell. 2004; 5(2):113-4. DOI: 10.1016/s1535-6108(04)00031-5. View